SCHEDULE: Pallotta Discloses 5.2% Stake in TriSalus Life Sciences

James J. Pallotta has reported beneficial ownership of 3,188,711 shares, representing 5.2% of TriSalus Life Sciences, Inc. common stock, including shares underlying warrants.

Summary

• James J. Pallotta has filed a Schedule 13G, indicating beneficial ownership of 3,188,711 shares of TriSalus Life Sciences, Inc. common stock.
• This holding represents 5.2% of the class of securities.
• The reported shares include 114,268 shares underlying exercisable warrants.
• The percentage is calculated based on 61,416,535 shares outstanding as of May 8, 2026, plus the shares underlying warrants.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of ownership and does not provide new operational or financial performance information.

Positives

• James J. Pallotta has acquired a significant stake (5.2%) in TriSalus Life Sciences, Inc., which could signal confidence in the company's future prospects.
• The inclusion of exercisable warrants in the beneficial ownership calculation suggests potential for further investment and increased stake.

Risks

• The filing does not explicitly detail any risks associated with this ownership stake or the company's operations.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from the company.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders acquiring more than 5% of a company's stock. This filing indicates James J. Pallotta's substantial investment in TriSalus Life Sciences, Inc., a biotechnology or life sciences company, which is a sector often subject to significant investor interest based on pipeline developments and clinical trial results.

Stakeholder Impact

• Shareholders: The increased stake by a notable investor may influence market perception and potentially lead to increased trading volume.
• Management: May face increased scrutiny or engagement from a significant shareholder.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from James J. Pallotta for any changes in beneficial ownership.
• Observe TriSalus Life Sciences, Inc.'s performance and disclosures for insights into the company's strategic direction and financial health.

Key Dates

Keywords

TriSalus Life Sciences, Schedule 13G, James J. Pallotta, Beneficial Ownership, Common Stock, Warrants, SEC Filing